All data are based on the daily closing price as of March 28, 2025
s

Sawai Group Holdings

4887.TSE
13.59 USD
-0.34
-2.44%

Overview

Last close
13.59 usd
Market cap
1.57B usd
52 week high
14.62 usd
52 week low
9.63 usd
Target price
17.02 usd

Valuation

P/E
16.9496
Forward P/E
16.7785
Price/Sales
1.284
Price/Book Value
1.2209
Enterprise Value
1.95B usd
EV/Revenue
1.5847
EV/EBITDA
7.5247

Key financials

Revenue TTM
1.23B usd
Gross Profit TTM
384.92M usd
EBITDA TTM
257.68M usd
Earnings per Share
0.81 usd
Dividend
0.32 usd
Total assets
2.30B usd
Net debt
366.76M usd

About

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
  • Symbol
    4887.TSE
  • Exchange
    TSE
  • Isin
    JP3323040000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Mitsuo Sawai
  • Headquarter
    Osaka
  • Web site
    https://www.sawaigroup.holdings
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top